Aurobindo Pharma Limited has announced the incorporation of a new, wholly owned subsidiary in India, named Auropharm Overseas Limited. The subsidiary’s objective is to undertake manufacturing and marketing operations both domestically and internationally. This strategic move signifies the company’s commitment to expanding its operational footprint and potentially entering new markets or enhancing existing ones.
Aurobindo Pharma Establishes New Subsidiary
Aurobindo Pharma Limited has officially incorporated a new wholly owned subsidiary in India. The newly established entity, named Auropharm Overseas Limited, was incorporated on August 13, 2026. This development marks a strategic step for the company in bolstering its global presence and operational capabilities.
Strategic Objectives of the New Entity
The primary object for the incorporation of Auropharm Overseas Limited is to engage in manufacturing and marketing operations. These operations are intended to span both the Indian domestic market and international territories. This expansion is aligned with Aurobindo Pharma’s ongoing growth strategy and its commitment to enhancing its market reach and product offerings across diverse geographical regions.
Financial and Structural Details
The incorporation involved an initial subscription to the share capital amounting to ₹10,00,000. This capital was divided into 1,00,000 equity shares of ₹10 each, representing a 100% shareholding by Aurobindo Pharma Limited. As the company was newly incorporated, details regarding its past turnover or financial history are not applicable.
Source: BSE
